Guardant Health (NASDAQ:GH) Shares Gap Up to $16.07

Guardant Health, Inc. (NASDAQ:GH) shares gapped up before the market opened on Monday . The stock had previously closed at $16.07, but opened at $16.78. Guardant Health shares last traded at $16.96, with a volume of 663,410 shares changing hands.

Analyst Ratings Changes

GH has been the subject of a number of research analyst reports. Canaccord Genuity Group cut their target price on shares of Guardant Health from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Friday, February 23rd. Piper Sandler cut their target price on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday, February 26th. The Goldman Sachs Group cut their target price on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Monday, April 15th. JPMorgan Chase & Co. cut their target price on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Finally, Guggenheim reiterated a “neutral” rating on shares of Guardant Health in a research note on Friday, April 5th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $40.40.

Guardant Health Stock Performance

The stock has a market capitalization of $2.08 billion, a P/E ratio of -3.96 and a beta of 0.87. The company has a debt-to-equity ratio of 7.18, a quick ratio of 6.24 and a current ratio of 6.54. The business’s fifty day moving average price is $19.21 and its two-hundred day moving average price is $23.19.

Guardant Health (NASDAQ:GH) last announced its earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.65). The firm had revenue of $155.05 million during the quarter, compared to analyst estimates of $151.71 million. Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. As a group, sell-side analysts forecast that Guardant Health, Inc. will post -3.49 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Kumud Kalia acquired 2,187 shares of the business’s stock in a transaction on Monday, March 18th. The stock was bought at an average price of $17.82 per share, with a total value of $38,972.34. Following the completion of the acquisition, the insider now owns 12,722 shares of the company’s stock, valued at $226,706.04. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Guardant Health

Institutional investors have recently modified their holdings of the stock. CWM LLC boosted its position in Guardant Health by 137.1% during the third quarter. CWM LLC now owns 984 shares of the company’s stock worth $29,000 after acquiring an additional 569 shares during the last quarter. BluePath Capital Management LLC purchased a new position in Guardant Health during the third quarter worth about $35,000. Headlands Technologies LLC raised its stake in Guardant Health by 362.3% during the fourth quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock worth $64,000 after purchasing an additional 1,844 shares during the period. Van ECK Associates Corp raised its stake in Guardant Health by 29.4% during the fourth quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock worth $73,000 after purchasing an additional 614 shares during the period. Finally, Nisa Investment Advisors LLC raised its stake in Guardant Health by 26.1% during the third quarter. Nisa Investment Advisors LLC now owns 3,450 shares of the company’s stock worth $102,000 after purchasing an additional 713 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.